CA2703230A1 - Novel crystalline forms - Google Patents

Novel crystalline forms Download PDF

Info

Publication number
CA2703230A1
CA2703230A1 CA2703230A CA2703230A CA2703230A1 CA 2703230 A1 CA2703230 A1 CA 2703230A1 CA 2703230 A CA2703230 A CA 2703230A CA 2703230 A CA2703230 A CA 2703230A CA 2703230 A1 CA2703230 A1 CA 2703230A1
Authority
CA
Canada
Prior art keywords
bosentan
crystalline form
process according
solid
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2703230A
Other languages
English (en)
French (fr)
Inventor
Abhay Gaitonde
Bindu Manojkumar
Sandeep Mekde
Prakash Bansode
Dattatraya Shinde
Sunanda Phadtare
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generics UK Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2703230A1 publication Critical patent/CA2703230A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2703230A 2007-10-24 2008-10-24 Novel crystalline forms Abandoned CA2703230A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2108/MUM/2007 2007-10-24
IN2108MU2007 2007-10-24
PCT/GB2008/050986 WO2009053748A2 (en) 2007-10-24 2008-10-24 Novel crystalline forms

Publications (1)

Publication Number Publication Date
CA2703230A1 true CA2703230A1 (en) 2009-04-30

Family

ID=40262729

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2703230A Abandoned CA2703230A1 (en) 2007-10-24 2008-10-24 Novel crystalline forms

Country Status (8)

Country Link
US (1) US8530488B2 (https=)
EP (1) EP2222649A2 (https=)
JP (1) JP2011500780A (https=)
CN (1) CN101939303B (https=)
AU (1) AU2008315757A1 (https=)
CA (1) CA2703230A1 (https=)
NZ (2) NZ585438A (https=)
WO (1) WO2009053748A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008247169B2 (en) * 2007-05-08 2013-09-12 Generics [Uk] Limited Polymorphic forms of bosentan
US8664390B2 (en) * 2007-06-29 2014-03-04 Generics (Uk) Limited Process for the introduction of hydroxyethoxy side chain in bosentan
JP2011500780A (ja) * 2007-10-24 2011-01-06 ジェネリクス・（ユーケー）・リミテッド 新規結晶形
JP5535082B2 (ja) * 2008-01-01 2014-07-02 シプラ・リミテッド ボセンタン、その多形形態及びその塩の合成方法
EP2240469A2 (en) 2008-01-24 2010-10-20 Actavis Group PTC EHF Substantially pure and a stable crystalline form of bosentan
JP5683276B2 (ja) 2008-02-08 2015-03-11 ジェネリクス・［ユーケー］・リミテッド ボセンタンの製造方法
WO2010032261A1 (en) 2008-08-12 2010-03-25 Cadila Healthcare Limited Process for preparation of bosentan
WO2010061210A1 (en) 2008-11-03 2010-06-03 Generics [Uk] Limited Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
WO2012002547A1 (ja) * 2010-07-02 2012-01-05 富士化学工業株式会社 ボセンタン固体分散体
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
PL402305A1 (pl) * 2012-12-30 2014-07-07 Instytut Farmaceutyczny Sposób wytwarzania bozentanu w postaci monohydratu o czystości farmaceutycznej

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2570699B1 (fr) * 1984-09-24 1987-08-28 Roussel Uclaf Nouveau procede de preparation de derives du 4h-1,2,4-triazole, nouveaux triazoles ainsi obtenus, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5276004A (en) * 1987-03-20 1994-01-04 Dai Nippon Insatsu Kabushiki Kaisha Process for heat transfer recording
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5739333A (en) * 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
US6136971A (en) * 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
EP2206497A1 (en) 1999-11-17 2010-07-14 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
CN1411373A (zh) 1999-12-16 2003-04-16 特瓦制药工业有限公司 制备来氟米特的新方法和新晶形的来氟米特
EP1254121B1 (en) 2000-01-25 2006-02-01 F. Hoffmann-La Roche Ag Preparation of sulfonamides
US6479692B1 (en) * 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
AU2003209669A1 (en) 2003-02-25 2004-09-17 Hetero Drugs Limited Amorphous form of losartan potassium
AU2003238664A1 (en) 2003-03-12 2004-09-30 Cadila Healthcare Limited Polymorphs and amorphous form of (s) - (+) -clopidogrel bisulfate
AU2003230195A1 (en) 2003-04-02 2004-10-25 Hetero Drugs Limited A novel process for amorphous form of donepezil hydrochloride
US20080188663A1 (en) * 2007-01-29 2008-08-07 Ashok Kumar Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I
US20080242687A1 (en) * 2007-04-02 2008-10-02 Auspex Pharmaceuticals, Inc. Substituted pyrimidines
AU2008247169B2 (en) 2007-05-08 2013-09-12 Generics [Uk] Limited Polymorphic forms of bosentan
US8664390B2 (en) 2007-06-29 2014-03-04 Generics (Uk) Limited Process for the introduction of hydroxyethoxy side chain in bosentan
US20110014291A1 (en) * 2007-10-11 2011-01-20 Actavis Group Ptc Ehf Novel Polymorphs of Bosentan
JP2011500780A (ja) * 2007-10-24 2011-01-06 ジェネリクス・（ユーケー）・リミテッド 新規結晶形
ES2376375T3 (es) 2007-12-18 2012-03-13 Dipharma Francis S.R.L. Procedimiento para la preparación de bosent�?n.
EP2240470A4 (en) 2008-01-10 2012-05-23 Msn Lab Ltd IMPROVED AND NEW PROCESS FOR THE PRODUCTION OF BOSENTANE
EP2240469A2 (en) 2008-01-24 2010-10-20 Actavis Group PTC EHF Substantially pure and a stable crystalline form of bosentan
JP5683276B2 (ja) 2008-02-08 2015-03-11 ジェネリクス・［ユーケー］・リミテッド ボセンタンの製造方法
EP2268634A2 (en) 2008-03-13 2011-01-05 Actavis Group PTC EHF Processes for the preparation of bosentan and related compounds using novel intermediates
EP2294056A1 (en) * 2008-05-23 2011-03-16 Synthon B.V. Bosentan salts
WO2010061210A1 (en) 2008-11-03 2010-06-03 Generics [Uk] Limited Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
IT1393136B1 (it) * 2009-03-11 2012-04-11 Sifa Vitor S R L Procedimento per la preparazione del bosentan

Also Published As

Publication number Publication date
AU2008315757A1 (en) 2009-04-30
EP2222649A2 (en) 2010-09-01
JP2011500780A (ja) 2011-01-06
CN101939303A (zh) 2011-01-05
US8530488B2 (en) 2013-09-10
NZ600010A (en) 2013-11-29
WO2009053748A2 (en) 2009-04-30
NZ585438A (en) 2012-09-28
US20100331352A1 (en) 2010-12-30
CN101939303B (zh) 2014-06-11
WO2009053748A3 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
US8530488B2 (en) Crystalline forms of bosentan
AU2008247169B2 (en) Polymorphic forms of bosentan
US20210317085A1 (en) Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
US20080161607A1 (en) Processes for preparation of polymorphic form II of sertraline hydrochloride
US20110263649A1 (en) Crystalline form of lenalidomide and a process for its preparation
KR20080015888A (ko) 카르베딜올
KR20040077872A (ko) 카베디롤의 결정질 고체 및 그 제조 방법
US7994178B2 (en) Crystalline rosuvastatin calcium and compositions thereof for treatment of hyperlipidaemia
US20240208889A1 (en) Solid state forms of tapinarof
US20040235904A1 (en) Crystalline and amorphous solids of pantoprazole and processes for their preparation
US20060293377A1 (en) Amorphous and polymorphic forms of telmisartan sodium
US12534448B2 (en) Solid state form of lemborexant
US20040097528A1 (en) Crystalline solid famciclovir forms I, II, III and preparation thereof
US20250066327A1 (en) Solid state forms of danicopan and process thereof
KR20070088507A (ko) 카베딜올의 결정질 형태 및 이것의 제조 방법
US20220220149A1 (en) Solid state forms of sage-217 and processes for preparation thereof
AU2013200937A1 (en) Polymorphic forms of bosentan

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150217